GLP1R and obesity due to melanocortin 4 receptor deficiency: As such, GLP-1 RAs represent a preferred therapeutic strategy in both obesity and CKM management, aligning evidence-based outcomes with comprehensive patient care [38,55,56] [Figure 2].